Bioassay for total serum bioactivity of Atractylodes lancea

Na‐Bangchang, Kesara; Cheoymang, Anurak; Muhamad, Nadda; Kulma, Inthuon

doi:10.4103/japtr.japtr_431_22

Cited by 3 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The in vitro bioassay method for the determination of serum total AL bioactivity was according to the method of Cheoymang et al 12 Total AL bioactivity was determined in human serum samples based on inhibitory effects on the growth of cholangiocarcinoma cell line (CL6) and Staphylococcus aureus (ATCC 25923), using MTT assay. The calibration curve (0, 0.39, 0.78, 1.56, 3.13, 2.56, and 50 ng/µl) was linear with correlation coefficients ≥.990.…”

Section: Methodsmentioning

confidence: 99%

Pharmacokinetic Analysis of Prognostic Factors in Patients With Advanced-Stage Intrahepatic Cholangiocarcinoma Following the Administration of Capsule Formulation of the Standardized Extract of Atractylodes lancea (Thunb) DC

Saeheng,

Karbwang,

Cheomung

et al. 2024

Integr Cancer Ther

Self Cite

View full text Add to dashboard Cite

Background: A statistical model is essential in determining the appropriate predictive indicators for therapies in many types of cancers. Predictors have been compared favorably to the traditional systems for many cancers. Thus, this study has been proposed as a new standard approach. A recent study on the clinical efficacy of Atractylodes lancea (Thunb) DC. (AL) revealed the higher clinical benefits in patients with advanced-stage intrahepatic cholangiocarcinoma (ICC) treated with AL compared with standard supportive care. We investigated the relationships between clinical efficacy and pharmacokinetic parameters of serum bioactivity of AL and its active constituent atractylodin and determined therapeutic ranges. Methods: Group 1 of advanced-stage ICC patients received daily doses of 1000 mg of standardized extract of the capsule formulation of AL (CMC-AL) for 90 days. Group 2 received daily doses of 1000 mg of CMC-AL for 14 days, followed by 1500 mg for 14 days, and 2000 mg for 62 days. Group 3 (control group) received palliative care. Cox proportional hazard model and Receiver Operating Characteristic (ROC) were applied to determine the cut-off values of AUC0-inf, Cmax, and Cavg associated with therapeutic outcomes. Number needed to treat (NNT) and relative risk (RR) were also applied to determine potential predictors. Results: The AUC0-inf of total AL bioactivity of >96.71 µg hour/ml was identified as a promising predictor of disease prognosis, that is, progression-free survival (PFS) and disease control rate (DCR). Cmax of total AL bioactivity of >21.42 was identified as a predictor of the prognosis of survival. The therapeutic range of total AL bioactivity for PFS and DCR is 14.48 to 65.8 µg/ml, and for overall survival is 10.97 to 65.8 µg/ml. Conclusions: The predictors of ICC disease prognosis were established based on the pharmacokinetics of total AL bioactivity. The information could be exploited to improve the clinical efficacy of AL in patients with advanced-stage ICC. These predictors will be validated in a phase 2B clinical study. Trial Registration: TCTR20210129007 (TCTR: www.clinicaltrials.in.th).

show abstract

Section: Methodsmentioning

confidence: 99%

Pharmacokinetic Analysis of Prognostic Factors in Patients With Advanced-Stage Intrahepatic Cholangiocarcinoma Following the Administration of Capsule Formulation of the Standardized Extract of Atractylodes lancea (Thunb) DC

Saeheng,

Karbwang,

Cheomung

et al. 2024

Integr Cancer Ther

Self Cite

View full text Add to dashboard Cite

show abstract

Prognostic factors of clinical responses in patients with advanced-stage intrahepatic cholangiocarcinoma followingAtractylodes lanceaadministration: A phase 2A clinical trial

Saeheng¹,

Karbwang

Cheomung

et al. 2023

Preprint

View full text Add to dashboard Cite

A statistical model is essential in determining the appropriate predictive indicators for therapies in many types of cancers. Predictors have been compared favorably to the traditional systems for many cancers. Thus, this study has been proposed as an alternative or a new standard approach. A recent study on the clinical efficacy of Atractylodes lancea (Thunb) DC. (AL) revealed the higher clinical benefits in patients with advanced-stage intrahepatic cholangiocarcinoma (ICC) treated with AL compared with standard supportive care. we investigated the relationships between clinical efficacy and pharmacokinetic parameters of serum bioactivity of AL and its active constituent (atractylodin) and determined therapeutic ranges. The cox proportion hazard model and Receive Operating Characteristic (ROC) were applied to determine the cut-off values of AUC0-inf, Cmax, and Cavg associated with therapeutic outcomes. Number-need to be treated (NNT) and relative risk (RR) was also applied to determine potential predictors. The AUC0-inf of total AL bioactivity of> 96.71 mg/h/l was identified as a promising predictor of disease prognosis, i.e., progression-free survival (PFS) and disease control rate (DCR). Cmax of total AL bioactivity of>21.42 was identified as a predictor of the prognosis of death. The therapeutic range of total AL bioactivity for PFS and DCR is 14.48-65.8 mg/l, and for overall survival is 10.97-65.8 mg/l. The predictors of ICC disease prognosis were established based on the pharmacokinetics of total AL bioactivity. The information could be exploited to improve the clinical efficacy of AL in patients with advanced-stage ICC. These predictors will be validated in a phase 2B clinical study.

show abstract

Correlation between antibacterial activity of twoArtemisiasp. extracts and their plant characteristics

Mashraqi

Abboud

Ismail

et al. 2023

Preprint

View full text Add to dashboard Cite

The present study evaluated the potential antibacterial activity of Artemisia absinthium L. and Artemisia herba-alba Asso. extracts through different organic and aqueous solvents. The tested bacteria were pathogenic types; Listeriamonocytogenes, Pseudomonas aeruginosa, Salmonella enterica and Staphylococcus aureus. There were different affinities for the studied organic solvents besides aqueous one. The comparative study was accomplished with comparing to the morphological, anatomical and palynological characters. The similarity parameter is obtained. ANOVA test analyzed MIC values for both plant extracts. Pearson Correlation Coefficients were determined for all both plant traits. MIC and MBC values were confirmed on using butanol and diethyl ether extracts besides butanol and chloroform extracts for Artemisia absinthium L. and Artemisia hera alba Asso against tested pathogenic bacteria respectively as an alternative natural antibacterial inhibitor agent.

show abstract

Bioassay for total serum bioactivity of Atractylodes lancea

Cited by 3 publications

References 15 publications

Pharmacokinetic Analysis of Prognostic Factors in Patients With Advanced-Stage Intrahepatic Cholangiocarcinoma Following the Administration of Capsule Formulation of the Standardized Extract of Atractylodes lancea (Thunb) DC

Pharmacokinetic Analysis of Prognostic Factors in Patients With Advanced-Stage Intrahepatic Cholangiocarcinoma Following the Administration of Capsule Formulation of the Standardized Extract of Atractylodes lancea (Thunb) DC

Prognostic factors of clinical responses in patients with advanced-stage intrahepatic cholangiocarcinoma followingAtractylodes lanceaadministration: A phase 2A clinical trial

Correlation between antibacterial activity of twoArtemisiasp. extracts and their plant characteristics

Contact Info

Product

Resources

About